Document
false0000105770 0000105770 2019-11-19 2019-11-19


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) – November 19, 2019
https://cdn.kscope.io/0b9c3dafcf2d3fa8f2cf5247d91fe9ea-form8k111919.jpg
WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)
 
 
 
 
 
 
 
Pennsylvania
 
1-8036
 
23-1210010
(State or other jurisdiction
of incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)
 
 
 
 
 
 
 
530 Herman O. West Drive,
Exton,
PA
 
 
 
19341-0645
(Address of principal executive offices)
 
 
 
(Zip Code)
 Registrant’s telephone number, including area code: 610-594-2900
Not Applicable
(Former name or address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, par value $0.25 per share
WST
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 

1



Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 19, 2019, Ms. Karen Flynn, Senior Vice President and Chief Commercial Officer, informed Mr. Eric Green, President and Chief Executive Officer of West Pharmaceutical Services, Inc. (the “Company”), of her intention to step down from her role and retire as of December 31, 2019.  In connection with Ms. Flynn’s retirement, Ms. Cindy Reiss-Clark has been promoted to Senior Vice President of Global Market Units and Commercial Solutions from her previous role of Vice President and General Manager of the Company’s Biologics Market Unit, and Mr. Christopher Ryan has been promoted to Senior Vice President of Commercial Products and Emerging Markets from his previous role of Vice President and General Manager of the Company’s Generics Market Unit.

Ms. Flynn’s decision to retire was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.



2






SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



 
WEST PHARMACEUTICAL SERVICES, INC.
 
 
 
 
 
/s/ George L. Miller
 
George L. Miller
 
Senior Vice President, General Counsel and Corporate Secretary
 
 
 
 
November 21, 2019
 




3